Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol 2017 Feb 2 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/28162999.
Compare quality appraisals for each clinical question
- What is the role of adjuvant systemic therapy in patients with resected stage II and stage III melanoma?